![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1766235
ÃÊÀ½ÆÄ Á¶Á÷ ÀýÁ¦ ½Ã½ºÅÛ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)Ultrasonic Tissue Ablation System Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
¼¼°èÀÇ ÃÊÀ½ÆÄ Á¶Á÷ ÀýÁ¦ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â 5¾ï 1,910¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, CAGR 8.7%¸¦ ³ªÅ¸³» 2034³â¿¡´Â 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ·¯ÇÑ Å« ¼ºÀåÀº ÁÖ·Î ½Å°æÇÐÀû Ä¡·áÀÇ ºóµµ Áõ°¡, ºñ¾Ï¼º Áúȯ¿¡¼ ÃÊÀ½ÆÄ ÀýÁ¦ ½Ã½ºÅÛÀÇ ¹üÀ§ È®´ë, ÀåÄ¡ ±â¼úÀÇ Áö¼ÓÀûÀÎ Áøº¸¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¶ÇÇÑ, ÀڱñÙÁ¾, Àü¸³¼± ºñ´ëÁõ(BPH), Àڱ󻸷Áõ, ½ÉÀå ºÎÁ¤¸Æ µîÀÇ Áúȯ¿¡ ´ëÇØ¼, ÃÊÀ½ÆÄ ÀýÁ¦ ½Ã½ºÅÛÀÌ Á¾¾çÇÐ ÀÌ¿ÜÀÇ ¿µ¿ª¿¡µµ Àû¿ëµÇ°Ô µÇ¾î, ÀÓ»ó ÀÌ¿ëÀÇ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ ´Ù¿ëµµ ¹× ºñħ½À¼ºÀº ´Ù¾çÇÑ ÀÇ·á Àü¹® ºÐ¾ß¿¡ ¸Å¿ì ¸Å·ÂÀûÀÌ¸ç ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ÃÊÀ½ÆÄ ¹× MRI¿Í °°Àº ½Ç½Ã°£ À̹Ì¡ ½Ã½ºÅÛ°ú ÈÞ´ë¿ë ÀÚµ¿ÈµÈ ¿¡³ÊÁö º¯Á¶ ½Ã½ºÅÛÀÇ °³¹ßÀ» ÅëÇØ Çâ»óµÈ Ÿ°ÙÆÃ Á¤È®µµ¸¦ Çâ»ó½ÃÅ´À¸·Î½á ÀÌ·¯ÇÑ Á¶Ä¡ÀÇ ¾ÈÀü¼º°ú È¿À²¼ºÀ» ÇöÀúÇÏ°Ô ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¶ÇÇÑ ÀÇ·á±â±â¸¦ º¸´Ù »ç¿ëÇϱ⠽±°í, »ç¿ëÇϱ⠽±°í, Ãß°¡ ÀÇ·á ÇöÀå¿¡¼ÀÇ Ã¤¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇÏ´Â °í¹Ðµµ ÃÊÁ¡ ÃÊÀ½ÆÄ(HIFU) ½Ã½ºÅÛÀº ºñħ½ÀÀû Á¢±Ù¹ý°ú ÁÖº¯ Á¶Á÷À» ¼Õ»ó½ÃŰÁö ¾Ê°í ¹Î°¨ÇÑ ºÎÀ§¸¦ Ä¡·áÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 5¾ï 1,910¸¸ ´Þ·¯ |
¿¹Ãø ±Ý¾× | 12¾ï ´Þ·¯ |
CAGR | 8.7% |
°í°µµ Áý¼Ó ÃÊÀ½ÆÄ(HIFU) ½Ã½ºÅÛ ºÐ¾ß´Â 2024³â¿¡ 2¾ï 6,080¸¸ ´Þ·¯ÀÇ ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç ³ú, Àü¸³¼±, Àڱà µî ¹Î°¨ÇÏ°í ¹Î°¨ÇÑ ¿µ¿ª¿¡¼ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿ä¹ý¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ºÎÀΰú ¿µ¿ª¿¡¼´Â HIFU´Â ÀÚ±ÃÀ» ¿ÂÁ¸ÇÏ°í ºñħ½ÀÀûÀÎ Á¢±ÙÀ» Á¦°øÇϱ⠶§¹®¿¡ ÀڱñÙÁ¾ÀÇ Ä¡·á¹ýÀ¸·Î¼ ±Þ¼ÓÈ÷ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÄŲ½¼º´À̳ª º»Å¼º ÁøÀü°ú °°Àº ½Å°æ ÁúȯÀÇ Ä¡·á¿¡µµ, ƯÈ÷ MRI °¡À̵å¿Í Á¶ÇÕÇßÀ» °æ¿ì¿¡ ÀαⰡ ³ô½À´Ï´Ù.
ºÎÀΰú ºÐ¾ß´Â 2024³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, 2034³â¿¡´Â 3¾ï 7,060¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀûÀÎ ¼±ÅÃÀ» ¿ä±¸ÇÏ´Â ¿©¼ºÀÌ ´Ã°í ÀÖ´Â °¡¿îµ¥, °í°µµ Áý¼Ó ÃÊÀ½ÆÄ(HIFU)´Â Àڱà ÀûÃâÀ̳ª ÀڱñÙÁ¾ ÇÙÃâ¼ú°ú °°Àº Á¾·¡ÀÇ ¼ö¼úÀû ¹æ¹ý¿¡ ºñÇØ Àúħ½ÀÀûÀÎ ¼±ÅÃÁö¸¦ Á¦°øÇØ, Å« ÁöÁö¸¦ ¾ò°í ÀÖ½À´Ï´Ù.
2024³â ¹Ì±¹ÀÇ ÃÊÀ½ÆÄ Á¶Á÷ ÀýÁ¦ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 1¾ï 6,230¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â À¯¸®ÇÑ »óȯ Á¤Ã¥, Àúħ½À ¶Ç´Â ºñħ½ÀÀÇ Ä¡·á¿¡ ´ëÇÑ ±âÈ£°¡ ³ô¾ÆÁü¿¡ µû¶ó ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸®¾óŸÀÓ À̹Ì¡ ±â¼úÀÇ ÅëÇÕ¿¡ ÀÇÇØ ¼ö±âÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óÇϰí, Çコ Äɾî ÇÁ·Î¹ÙÀÌ´õ¿Í ±â±â Á¦Á¶¾÷ü°£ÀÇ Çù·ÂÀûÀÎ ´ëó¿¡ ÀÇÇØ µ¿±¹¿¡ ÀÖ¾î¼ÀÇ ÃÊÀ½ÆÄ Á¶Á÷ ÀýÁ¦ ½Ã½ºÅÛÀÇ ¹üÀ§°¡ ÇÑÃþ ´õ È®´ëÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ÃÊÀ½ÆÄ Á¶Á÷ ÀýÁ¦ ½Ã½ºÅÛ ½ÃÀå ÁÖ¿ä ±â¾÷Àº FUSMobile, bioventus, BRAINSONIX, EDAP TMS, INSIGHTEC, Haifu, Soring, Verasonics, STRYKER, PROFOUND, OLYMPUS, sonablate, ASTAR, INTEGRA µîÀÌ ÀÖ½À´Ï´Ù. È®ÀåÀ» À§ÇÑ Àü·«Àû Á¢±Ù¹ý¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¸¦ Á¦°øÇϴ ÷´Ü Àåºñ¸¦ µµÀÔÇϱâ À§ÇØ Áö¼ÓÀûÀÎ R&D¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿ªµ¿ÀûÀÎ ½Ã½ºÅÛÀ» ¸¸µé±â À§ÇØ È¯ÀÚÀÇ Æí¾ÈÇÔÀ» °³¼±Çϰí Ä¡·á ½Ã°£À» ´ÜÃàÇÏ°í ¾ÈÀü ÇÁ·ÎÅäÄÝÀ» °ÈÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.
The Global Ultrasonic Tissue Ablation System Market was valued at USD 519.1 million in 2024 and is estimated to grow at a CAGR of 8.7% to reach USD 1.2 billion by 2034. This significant growth is primarily driven by the increasing frequency of neurological procedures, the expanding scope of ultrasound ablation systems in non-cancerous diseases, and ongoing advancements in device technologies. Additionally, ultrasound ablation systems are being increasingly applied outside oncology for conditions like uterine fibroids, benign prostatic hyperplasia (BPH), endometriosis, and even cardiac arrhythmias, contributing to their wider clinical use. The versatility and non-invasive nature of these devices make them highly attractive for various medical specialties, further driving market growth.
Improvements in targeting precision, bolstered by real-time imaging systems like ultrasound and MRI, as well as the development of portable and automated energy modulation systems, have significantly enhanced the safety and efficacy of these procedures. These innovations have also made the devices more accessible and user-friendly, encouraging their adoption in additional healthcare settings. High-intensity focused ultrasound (HIFU) systems, which represent the largest segment in this market, continue to gain popularity due to their non-invasive approach and ability to treat sensitive areas without damaging surrounding tissue.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $519.1 Million |
Forecast Value | $1.2 Billion |
CAGR | 8.7% |
The high-intensity focused ultrasound (HIFU) systems segment held a major market share of USD 260.8 million in 2024, showing increasing use in delicate and sensitive areas, including the brain, prostate, and uterus. HIFU systems are now commonly used to treat cancers such as liver, kidney, and prostate, particularly in patients who are unable or unwilling to undergo surgery. In gynecology, HIFU is rapidly becoming the preferred method for treating uterine fibroids, as it offers a uterus-preserving and non-invasive approach. Additionally, it is gaining traction for the treatment of neurological disorders like Parkinson's disease and essential tremor, especially when combined with MRI guidance.
The gynecology segment held the largest market share in 2024 and is projected to reach USD 370.6 million by 2034. This sector is experiencing robust growth driven by the rising prevalence of uterine fibroids and endometriosis among women of reproductive age. As more women seek non-invasive alternatives, high-intensity focused ultrasound (HIFU) is gaining significant traction, offering a less invasive option compared to traditional surgical methods like hysterectomy and myomectomy.
U.S. Ultrasonic Tissue Ablation System Market was valued at USD 162.3 million in 2024. Demand for these systems is rising due to favorable reimbursement policies, as well as a growing preference for minimally invasive or non-invasive procedures. The U.S. healthcare system's increasing adoption of HIFU for various indications, including prostate cancer, uterine fibroids, and neurological disorders, is driving product uptake. Integration of real-time imaging technologies is improving procedural accuracy and safety, while collaborative efforts between healthcare providers and device manufacturers are further expanding the scope of ultrasonic tissue ablation systems in the country.
Key players in the Global Ultrasonic Tissue Ablation System Market include names like FUSMobile, bioventus, BRAINSONIX, EDAP TMS, INSIGHTEC, Haifu, Soring, Verasonics, STRYKER, PROFOUND, OLYMPUS, sonablate, ASTAR, and INTEGRA. In the competitive ultrasonic tissue ablation market, companies are focusing on strategic approaches to maintain and expand their market share. Collaborations and partnerships with healthcare providers are being actively pursued to enhance clinical applications and broaden the use of ultrasonic systems. Key players are investing in continuous research and development to introduce advanced devices that integrate real-time imaging and provide more accurate treatment targeting. Expanding their product portfolios, some companies are introducing portable versions of their ablation systems to cater to outpatient settings. Moreover, several manufacturers are focusing on improving patient comfort, reducing procedure time, and enhancing safety protocols to make their systems more appealing to healthcare professionals. Additionally, by offering training and educational programs to clinicians and healthcare providers, these companies aim to increase adoption rates and build brand loyalty.